A Phase 3 interventional study of Recombinant staphylokinase and Alteplase in Ischemic Stroke, sponsored by Supergene, LLC. Completed at 18 sites in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-02.
Sponsored by Supergene, LLC · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Ischemic Stroke with a site in Russian Federation — 4 open to participants now, 4 under way, none of them phase 3. Ischemic Stroke · Russian Federation.
Among the 26 studies in Ischemic Stroke with a site in Russian Federation, this one is the 6th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2017, is one of 8 in phase 3, and was the 9th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →4 of the 26 studies in Ischemic Stroke with a site in Russian Federation are open now. Recruiting first, the newest first:
Neurotechnika · Sites in Russian Federation
Ages 18–80
Skolkovo Institute of Science and Technology · Sites in Russian Federation
Ages 35–70 · Healthy volunteers
Mikhail Zykov · Sites in Russian Federation
Ages 18+
Siberian Scientific Research and Test Center for Biomedical Engineering · Sites in Russian Federation
Ages 35–65 · Healthy volunteers
A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 336 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 120 across the 19 interventional studies, 500 across the 7 observational. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 26 have an industry lead sponsor. The 10 most frequent:
Supergene, LLC is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Supergene, LLC has 3 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 26 studies in Ischemic Stroke with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of the study is to determine if single-bolus recombinant nonimmunogenic staphylokinase is effective and save thrombolytic agent in patients with ischemic stroke in comparison to alteplase.
Experimental Drug Profile. The active substance of Fortelyzin is Forteplase. It's recombinant protein which contains aminoacid sequence of staphylokinase. It is single chain molecula, consists of 138 aminoacids, weight 15.5 kDa. When staphylokinase is added to human plasma containing a fibrin clot, it preferentially reacts with plasmin at the clot surface, forming a plasmin-staphylokinase complex. This complex activates plasminogen trapped in the thrombus. The plasmin-staphylokinase complex and plasmin bound to fibrin are protected from inhibition by alpha2-antiplasmin. Once liberated from the clot (or generated in plasma), however, they are rapidly inhibited by alpha2-antiplasmin. This selectivity of action confines the process of plasminogen activation to the thrombus, preventing excessive plasmin generation, alpha2-antiplasmin depletion, and fibrinogen degradation in plasma. In rabbits anti forteplase antibodies are not produced. It was achieved by replacement of amino acids in immunogenic epitop of molecule staphylokinase. Blood fibrinogen decrease after i.v. injection of Fortelyzin less 10% within first 24 hours. Angiographic data suggests that restoration of coronary blood flow appears in up to 80% of patients with STEMI after i.v. injection of Fortelyzin.
Main goals of the study are to prove an efficacy of the single-bolus intravenous injection of recombinant nonimmunogenic staphylokinase (Fortelyzin) in comparison with bolus infusion alteplase(Actilyse) in patients with ischemic stroke.
To prove a safety and to assess possible adverse events in the single-bolus intravenous injection of recombinant nonimmunogenic staphylokinase (Fortelyzin) in comparison with bolus infusion alteplase (Actilyse) in patients with ischemic stroke.
Study Design. All eligible patients will be randomized in two equal groups for administration recombinant nonimmunogenic staphylokinase (Fortelyzin) or alteplase (Actilyse) by using "envelope method" of randomization. It is an open-lable study. Each of agents will be administered no longer then 4,5 hours from symptoms onset. Comparative agent will be administered as prescribed in its instructions. All patients will be examination for 90 days
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lyophilizate for solution making for intravenous injection, 5 mg (745000 ME). 10 mg of drug reconstituted in 10 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
Drug: Recombinant staphylokinase
Intravenous alteplase 0.9 mg/kg (10% bolus and 90% as IV infusion over 1 hour, maximum 90 mg)
Drug: Alteplase
10 mg of drug reconstituted in 10 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
Also known as: Fortelyzin
Intravenous alteplase 0.9 mg/kg (10% bolus and 90% as IV infusion over 1 hour, maximum 90 mg)
Also known as: Actilyse
Good Functional Recovery
The number of patients with Modified Rankin Scale (mRS) scores 0-1 on day 90 after drug administration, where 0 - No symptoms, 1 - No significant disability. All scale is 0 - No symptoms, 1 - No significant disability, 2 - Slight disability, 3 - Moderate disability, 4 - Moderately severe disability, 5 - Severe disability, 6 - Dead.
Time frame: within 90 days after fibrinolysis
The Number of Patients With Modified Rankin Scale (0-1) + NIHSS (0-1) + Barthel (95-100)
Composite endpoint, included the number of patients reached Modified Rankin scale 0-1 score, NIHSS 0-1 score and Barthel index 95-100. Modified Rankin scale: 0 - No symptoms, 1 - No significant disability, 2 - Slight disability, 3 - Moderate disability, 4 - Moderately severe disability, 5 - Severe disability, 6 - Dead. The National Institutes of Health Stroke Scale (NIHSS): 0 - No stroke symptoms, 1-4 - Minor stroke, 5-15 - Moderate stroke, 16-20 - Moderate to severe stroke, 21-42 - Severe stroke. Barthel index: 80-100 - Independent, 60-79 - Minimally dependent, 40-59 - Partially dependent, 20-39 - Very dependent, \<20 - Totally dependent.
Time frame: within 90 days after fibrinolysis
The Median of NIHSS After 24 Hours
The median of The National Institutes of Health Stroke Scale (NIHSS) at 24 h after drug administration, where: 0 - No stroke symptoms, 1-4 - Minor stroke, 5-15 - Moderate stroke, 16-20 - Moderate to severe stroke, 21-42 - Severe stroke.
Time frame: after 24 hours
The Median of NIHSS After 90 Days
The median of The National Institutes of Health Stroke Scale (NIHSS) after 90 days of drug administration, where: 0 - No stroke symptoms, 1-4 - Minor stroke, 5-15 - Moderate stroke, 16-20 - Moderate to severe stroke, 21-42 - Severe stroke.
Time frame: within 90 days after fibrinolysis
All Cause Death
Death caused by any event
Time frame: within 90 days after fibrinolysis
Intracranial Haemorrhage
The number of intracranial hemorrhage (events)
Time frame: within 90 days after fibrinolysis
Symptomatic Intracranial Haemorrhage
The number of symptomatic intracranial haemorrhage according to ECASS III definition (events). The ECASS III definition of symptomatic intracranial haemorrhage was any haemorrhage with neurologic deterioration, as indicated by an NIHSS score that was higher by 4 points or more than the value at baseline or the lowest value in the first 7 days, or any haemorrhage leading to death. In addition, the haemorrhage must have been identified as the predominant cause of the neurologic deterioration.
Time frame: within 90 days after fibrinolysis
| Milestone | Recombinant Staphylokinase | Actilyse |
|---|---|---|
| Started | 168 | 168 |
| Completed | 168 | 168 |
| Not completed | 0 | 0 |
The number of patients with Modified Rankin Scale (mRS) scores 0-1 on day 90 after drug administration, where 0 - No symptoms, 1 - No significant disability. All scale is 0 - No symptoms, 1 - No significant disability, 2 - Slight disability, 3 - Moderate disability, 4 - Moderately severe disability, 5 - Severe disability, 6 - Dead.
| patients | Recombinant Staphylokinase | Actilyse |
|---|---|---|
| Good Functional Recovery | 84 | 68 |
Composite endpoint, included the number of patients reached Modified Rankin scale 0-1 score, NIHSS 0-1 score and Barthel index 95-100. Modified Rankin scale: 0 - No symptoms, 1 - No significant disability, 2 - Slight disability, 3 - Moderate disability, 4 - Moderately severe disability, 5 - Severe disability, 6 - Dead. The National Institutes of Health Stroke Scale (NIHSS): 0 - No stroke symptoms, 1-4 - Minor stroke, 5-15 - Moderate stroke, 16-20 - Moderate to severe stroke, 21-42 - Severe stroke. Barthel index: 80-100 - Independent, 60-79 - Minimally dependent, 40-59 - Partially dependent, 20-39 - Very dependent, \<20 - Totally dependent.
| patients | Recombinant Staphylokinase | Actilyse |
|---|---|---|
| The Number of Patients With Modified Rankin Scale (0-1) + NIHSS (0-1) + Barthel (95-100) | 59 | 52 |
The median of The National Institutes of Health Stroke Scale (NIHSS) at 24 h after drug administration, where: 0 - No stroke symptoms, 1-4 - Minor stroke, 5-15 - Moderate stroke, 16-20 - Moderate to severe stroke, 21-42 - Severe stroke.
| score | Recombinant Staphylokinase | Actilyse |
|---|---|---|
| The Median of NIHSS After 24 Hours | 6 (3 to 11) | 6 (3 to 12) |
The median of The National Institutes of Health Stroke Scale (NIHSS) after 90 days of drug administration, where: 0 - No stroke symptoms, 1-4 - Minor stroke, 5-15 - Moderate stroke, 16-20 - Moderate to severe stroke, 21-42 - Severe stroke.
| score | Recombinant Staphylokinase | Actilyse |
|---|---|---|
| The Median of NIHSS After 90 Days | 2 (1 to 5) | 2 (1 to 5) |
Death caused by any event
| patients | Recombinant Staphylokinase | Actilyse |
|---|---|---|
| All Cause Death | 17 | 24 |
The number of intracranial hemorrhage (events)
| events | Recombinant Staphylokinase | Actilyse |
|---|---|---|
| Intracranial Haemorrhage | 31 | 28 |
The number of symptomatic intracranial haemorrhage according to ECASS III definition (events). The ECASS III definition of symptomatic intracranial haemorrhage was any haemorrhage with neurologic deterioration, as indicated by an NIHSS score that was higher by 4 points or more than the value at baseline or the lowest value in the first 7 days, or any haemorrhage leading to death. In addition, the haemorrhage must have been identified as the predominant cause of the neurologic deterioration.
| events | Recombinant Staphylokinase | Actilyse |
|---|---|---|
| Symptomatic Intracranial Haemorrhage | 5 | 13 |
Collected over 90 days after fibronolysis. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Recombinant Staphylokinase | 17/168 (10.1%) | 22/168 (13.1%) | 7/168 (4.2%) |
| Actilyse | 24/168 (14.3%) | 38/168 (22.6%) | 8/168 (4.8%) |
| Event | Recombinant Staphylokinase | Actilyse |
|---|---|---|
| Cerebral oedemaNervous system disorders | 7/168 | 14/168 |
| Symptomatic intracranial haemorrhageNervous system disorders | 5/168 | 13/168 |
| SurgeryNervous system disorders | 5/168 | 3/168 |
| Pulmonary thromboembolismBlood and lymphatic system disorders | 1/168 | 3/168 |
| NeurosurgeryNervous system disorders | 2/168 | 1/168 |
| Gastric ulcerGastrointestinal disorders | 0/168 | 2/168 |
| Acute myocardial infarctionCardiac disorders | 1/168 | 1/168 |
| New acute ischaemic strokeNervous system disorders | 1/168 | 0/168 |
| Takotsubo cardiomyopathyCardiac disorders | 0/168 | 1/168 |
| Event | Recombinant Staphylokinase | Actilyse |
|---|---|---|
| HaematuriaRenal and urinary disorders | 7/168 | 8/168 |
| Age, Categorical(Participants) | Recombinant Staphylokinase | Actilyse | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 84 | 80 | 164 |
| >=65 years | 84 | 88 | 172 |
| Age, Continuous(years) | Recombinant Staphylokinase | Actilyse | Total |
|---|---|---|---|
| Mean | 64.4 ± 9.6 | 64.6 ± 10.6 | 64.5 ± 10.1 |
| Sex: Female, Male(Participants) | Recombinant Staphylokinase | Actilyse | Total |
|---|---|---|---|
| Female | 106 | 112 | 218 |
| Male | 62 | 56 | 118 |
| Race and Ethnicity Not Collected(Participants) | Recombinant Staphylokinase | Actilyse | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(Participants) | Recombinant Staphylokinase | Actilyse | Total |
|---|---|---|---|
| Russia | 168 | 168 | 336 |
| Baseline NIHSS score(score) | Recombinant Staphylokinase | Actilyse | Total |
|---|---|---|---|
| Median | 11 (8 to 14) | 11 (8 to 16) | 11 (8 to 15) |
| Baseline mRS score(score) | Recombinant Staphylokinase | Actilyse | Total |
|---|---|---|---|
| Median | 4 (4 to 5) | 4 (4 to 5) | 4 (4 to 5) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2017 to primary completion in Mar 2019, 24 months.
Results were first posted in Apr 2025, 6 years after primary completion.
Of 167 phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's 24 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: auR protein, Staphylococcus aureus
Supergene, LLC